Lv5
948 积分 2022-07-15 加入
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer
6天前
已完结
Signaling scaffold Shoc2 regulates lymphangiogenesis by suppressing mTORC1-mediated IFN responses
29天前
已完结
SHOC2 Is a Novel Cause of Central Conducting Lymphatic Anomaly
29天前
已完结
Abstract 5518: Targeting FAK by Ifebemtinib synergizes with Pan RAS inhibitors in treating RAS mutant cancers
30天前
已完结
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers
1个月前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
2个月前
已完结
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
2个月前
已完结
Targeting SHOC2: a treatable therapeutic site in RAS(Q61) mutant cancers
3个月前
已完结
The Farnesyltransferase Inhibitor LB42708 Suppresses Vascular Endothelial Growth Factor-Induced Angiogenesis by Inhibiting Ras-dependent Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signal Pathways
4个月前
已完结
MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
5个月前
已完结
皖公网安备34019202002308
